Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 5.02, 9.01 · 8-K

Firefly Neuroscience, Inc.

AIFFNASDAQEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 8, 2026, the board of directors (the “Board”) of Firefly Neuroscience, Inc., a Delaware corporation (the “Company”), terminated Paul Krzywicki as Chief Financial Officer of the Company, effective September 24, 2026. Mr.…

Filed Sep 14, 2026Accepted Sep 14, 2026, 4:30 PM EDTCIK 803578Accession 0001213900-26-099733
Share

Company context

Current securities

Historical securities (2)

Recent company filings

  1. 10-Q filingAug 11, 2026
  2. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security HoldersAug 7, 2026
  3. DEF 14A filingJul 9, 2026
  4. 424B3 filingJul 2, 2026
  5. EFFECT filingJun 30, 2026

Registered securities in this filing

FIREFLY NEUROSCIENCE, INC. · 8-K · Filed 2026-09-14

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.0001 per share

Symbol
AIFF
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: AsOf2026-09-08

Dimensions: Not supplied

Accession 000121390026099733 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 5.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 8, 2026, the board of directors (the “Board”) of Firefly Neuroscience, Inc., a Delaware corporation (the “Company”), terminated Paul Krzywicki as Chief Financial Officer of the Company, effective September 24, 2026. Mr. Krzywicki’s termination was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. On the same date, the Nominating and Corporate Governance Committee of the Board recommended the appointment of Jessica Paz as Chief Accounting Officer of the Company, and the Board approved Ms. Paz’s appointment as Chief Accounting Officer of the Company. On September 8, 2026, the Compensation Committee of the Board approved and ratified an offer of employment extended to Ms. Paz, dated July 28, 2026 (the “Paz Offer of Employment”). Under the Paz Offer of Employment, Ms. Paz was employed as the Company’s Chief Accounting Officer effective September 8, 2026, at an annual base salary of $215,000. Pursuant to the Paz Offer of Employment, Ms. Paz was granted a stock option to purchase 50,000 shares of common stock of the Company under the Firefly Neuroscience, Inc. 2024 Long-Term Incentive Plan (as amended, the “Plan”) and the form of the stock option agreement approved for grants under the Plan, at an exercise price per share equal to the fair market value of the Company’s common stock on the date of grant. The option will vest over four years, with 25% of the shares vesting on the first anniversary of Ms. Paz’s vesting commencement date and the remaining shares vesting in equal quarterly installments over the following twelve quarters, subject to her continued employment with the Company through each applicable vesting date. Ms. Paz will be eligible to participate in the Company’s standard benefits covering employees at her level and will receive paid time off pursuant to the Company’s flexible PTO policy. Ms. Paz’s employment is at-will. Under an Indemnification Agreement between the Company and Ms. Paz in the Company’s standard form for officers or directors of the Company, dated as of September 8, 2026 (the “Paz Indemnification Agreement”), the Company agreed to indemnify Ms. Paz to the fullest extent permitted by applicable law against expenses, losses, liabilities, judgments, fines, penalties and amounts paid in settlement incurred by Ms. Paz in connection with any proceeding relating to her service as an officer of the Company. The Company will also advance all expenses incurred by Ms. Paz in connection with any such proceeding within twenty (20) days after receipt of Ms. Paz’s written request therefor, without regard to whether Ms. Paz will ultimately be entitled to be indemnified for such expenses. Any obligation to repay advances will be unsecured and interest-free. The Paz Indemnification Agreement also provides that if the Company or any of its subsidiaries maintains a directors’ and officers’ liability insurance policy, Ms. Paz will be covered by such policy in such a manner as to provide her the same rights and benefits as are accorded to the most favorably insured of the Company’s and its subsidiaries’ then current directors and officers. Ms. Paz and the Company also entered into an Employee Confidential Information and Inventions Assignment Agreement, dated as of September 9, 2026 (the “Paz Confidentiality Agreement”), which prohibits unauthorized use or disclosure of the Company’s proprietary information, and contains a general assignment of rights to inventions and intellectual property rights, non-competition provisions that apply during the term of employment, non-solicitation provisions that apply during the term of employment and for one year after the term of employment, and non-disparagement provisions that apply during and after the term of employment. The foregoing summary of the terms and conditions of the Paz Offer of Employment, the Paz Indemnification Agreement, and the Paz Confidentiality Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of each of the Paz Offer of Employment, the Paz Indemnification Agreement, and the Paz Confidentiality Agreement filed as Exhibit 10.1, Exhibit 10.2, and Exhibit 10.3 to this report, respectively, which is incorporated herein by reference. Ms. Paz, 46, most recently served as Senior Director of Accounting and Operations at Genvid Holdings, Inc., a technology company, from April 2020 to August 2026. From February 2019 to April 2020, Ms. Paz served as Global Financial Controller at VITECH Systems Group, Inc. From September 2016 to November 2018, Ms. Paz served as North America Controller, Global Payment Solutions at Finastra (formerly D+H Corporation). Earlier in her career, Ms. Paz held finance and accounting leadership positions at PEN American Center, Pro Mujer International Inc., Reboot Holdings Pty Ltd., and Kaplan, Inc. Ms. Paz holds a Master of Science in Accounting and Finance and a Master of Business Administration in Technology Management, each from SUNY Polytechnic Institute, and a Bachelor of Science in Accounting from Hunter College, City University of New York. There are no family relationships among Ms. Paz and any of the Company’s other executive officers or directors. There are and have been no transactions in which Ms. Paz has an interest requiring disclosure under Item 404(a) of Regulation S-K.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.